Sign In
Buy CHMA
$3.76
+0 (+0%)
At Close: May 27, 2022
Chiasma Announces FDA Approval of MYCAPSSA® (Octreotide) Capsules, the First and Only Oral Somatostatin Analog
05:28pm, Friday, 26'th Jun 2020
Chiasma, Inc. (CHMA), a commercial stage biopharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) approved MYCAPSSA®(octreotide) capsules for long-term maintenance
The Daily Biotech Pulse: Chiasma, Heron Await FDA Decisions, DBV Restructures, 3 Biopharmas Make Wall Street Debuts
12:28pm, Friday, 26'th Jun 2020
Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 25) * Brainstorm Cell Therapeutics Inc (NASDAQ: BCLI) *
The Daily Biotech Pulse: Chiasma, Heron Await FDA Decisions, DBV Restructures, 3 Biopharmas Make Wall Street Debuts
12:00am, Friday, 26'th Jun 2020
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs June 25)
Brainstorm Cell...
The Week Ahead In Biotech: Karyopharm, Zogenix, Heron, Chiasma On The Radar Ahead Of FDA Decisions
12:00am, Sunday, 21'st Jun 2020
Biotech stocks rebounded along with the broader market in the week ended June 19. The week was a busy one from the perspective of PDUFA dates, with the FDA issuing approvals...
Companies Like Chiasma (NASDAQ:CHMA) Are In A Position To Invest In Growth
10:14am, Tuesday, 16'th Jun 2020
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Edited Transcript of CHMA earnings conference call or presentation 7-May-20 9:00pm GMT
12:28am, Friday, 05'th Jun 2020
Q1 2020 Chiasma Inc Earnings Call
Attention Biotech Investors: Mark Your Calendar For June PDUFA Dates
12:00am, Monday, 01'st Jun 2020
Despite the FDA tied up with COVID-19-related activities, May turned out to be a positive month for biopharma companies from the perspective of drug approvals. Three new molecular...
Chiasma, Inc. (CHMA) CEO Raj Kannan on Q1 2020 Results - Earnings Call Transcript
04:04am, Monday, 11'th May 2020
Chiasma, Inc. (NASDAQ:CHMA) Q1 2020 Earnings Conference Call May 7, 2020 17:00 ET Company Participants Dawn Schottlandt - Vice President, IR & Corporate Com
Chiasma Inc (CHMA) Q1 2020 Earnings Call Transcript
08:30pm, Friday, 08'th May 2020
Image source: The Motley Fool. Chiasma Inc (NASDAQ: CHMA)Q1 2020 Earnings CallMay 7, 2020, 5:00 p.m. ETContents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: Operato
Chiasma Reports First Quarter 2020 Financial Results
08:05pm, Thursday, 07'th May 2020
NEEDHAM, Mass., May 07, 2020 -- Chiasma, Inc. (NASDAQ: CHMA), a clinical, late-stage biopharmaceutical company focused on improving the lives of patients who face challenges.
The Daily Biotech Pulse: FDA Approves Novartis Lung Cancer Drug, 2-Way Contest Emerging For Tetraphase Pharma, Dexcom To Join S&P 500
12:00am, Thursday, 07'th May 2020
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech stocks hitting 52-week highs May 6.)
Adverum Biotechnologies Inc...
IPO Update: Ayala Pharmaceuticals Launches IPO
09:31pm, Monday, 04'th May 2020
Ayala Pharmaceuticals has filed proposed terms for its $50 million U.S. IPO. The firm is advancing programs for the treatment of various cancers. For patient, l
The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace
12:00am, Sunday, 03'rd May 2020
Biotech stocks started last week on a strong note but the upward momentum slowed through the week. The week saw a slew of earnings from big pharma names, including Merck...
Chiasma To Report First Quarter Financial Results On May 7, 2020
08:01pm, Thursday, 30'th Apr 2020
NEEDHAM, Mass., April 30, 2020 -- Chiasma, Inc. (NASDAQ: CHMA), a clinical, late-stage biopharmaceutical company focused on improving the lives of patients with rare and.
Chiasma Appoints Anand Varadan as Chief Commercial Officer and Reports Inducement Grant under NASDAQ Listing Rule 5635(c)(4)
08:45pm, Wednesday, 22'nd Apr 2020
Chiasma, Inc. (CHMA), a clinical, late stage biopharmaceutical company focused on improving the lives of patients who face challenges associated with their existing treatments for rare and serious chr
